close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

336.64 -2.73 (-0.80%)
Streaming Delayed Price Updated: 10:34 AM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alnylam Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
Via Investor Brand Network
Topics Intellectual Property
News headline image
Drug-Delivery Breakthroughs, Cross-Indication Research Accelerate New Momentum in CNS and Oncology Development
From BioMedWire
Via GlobeNewswire
Alnylam Pharmaceuticals (NASDAQ:ALNY) Fits the 'Affordable Growth' GARP Profile ↗
Via Chartmill
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): A GARP Candidate with Strong Growth and Fair Valuation ↗
Via Chartmill
News headline image
Why Alnylam Pharmaceuticals Stock Was Soaring on Monday ↗
One pundit tracking the company upgraded his recommendation. 
Via The Motley Fool
News headline image
Why Alnylam Pharmaceuticals Stock Slipped Today ↗
The company's Amvuttra is proving to be quite the motor of growth these days. 
Via The Motley Fool
News headline image
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as... 
Via Finterra
Topics Economy Intellectual Property
News headline image
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Period Progress
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2025 Financial Results
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Should You Buy Alnylam Pharmaceuticals Before Feb. 12? ↗
Alnylam could have a catalyst on the way. 
Via The Motley Fool
Topics Earnings
News headline image
Alnylam Launches “Alnylam 2030” Strategy to Drive Next Era of Growth and Patient Impact
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam to Webcast Presentation at 44th Annual J.P. Morgan Healthcare Conference
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500
As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the... 
Via PredictStreet
Topics Economy Intellectual Property Stocks
News headline image
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY): A Prime GARP Candidate for Affordable Growth ↗
Alnylam Pharmaceuticals exemplifies the GARP strategy, offering strong growth and profitability at a reasonable price compared to biotech peers. 
Via Chartmill
News headline image
Is Alnylam Pharmaceuticals a Millionaire Maker? ↗
This hot biotech stock could have a lot more room to run. 
Via The Motley Fool
News headline image
Alnylam Pharmaceuticals Announces Changes to Board of Directors
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗
Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam. 
Via Investor's Business Daily
News headline image
Novo Nordisk's $100 Million Coramitug Shows Promise In Reducing Heart Failure Biomarker ↗
Novo Nordisk's Coramitug cut NT-proBNP levels and was well tolerated in a Phase 2 ATTR-CM trial, paving the way for its Phase 3 CLEOPATTRA study. 
Via Benzinga
News headline image
Got $5,000? 3 Top Growth Stocks to Buy That Could Double Your Money ↗
No investment is a slam dunk to double your money. But these great stocks appear to have what it takes. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Healthcare Sector Navigates Turbulent Waters: Innovation Surges Amidst Political Headwinds
New York, NY – November 10, 2025 – The S&P 500 Healthcare sector presented a mixed picture today, with the broader index showing a modest uptick while significant segments, particularly health insurers... 
Via MarketMinute
Topics Artificial Intelligence Economy Government
News headline image
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Intellia Therapeutics Crashes After A Patient In Its Pivotal Study Dies ↗
The company remains confident in its other gene-editing product, which would treat a swelling disorder. 
Via Investor's Business Daily
Topics Death
News headline image
What Does the Market Think About Alnylam Pharmaceuticals Inc? ↗
 
Via Benzinga
News headline image
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
From Alnylam Pharmaceuticals, Inc.
Via Business Wire
News headline image
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗
 
Via Benzinga
News headline image
Why Is Alnylam Pharmaceuticals Stock Trading Lower Thursday? ↗
Alnylam stock fell after a strong Q3 with $2.90 EPS and $1.25 billion revenue, a subpoena disclosure, and raised 2025 sales guidance to $3.6 billion–$3.8 billion. 
Via Benzinga
Topics Law Enforcement
News headline image
Meta Tumbles 10%, Google Marks Historic Rally: What's Moving Markets Thursday? ↗
Wall Street saw a cautious tone on Thursday as major tech-heavy indexes edged lower, weighed down by mixed earnings from the mega-caps and the lingering impact of hawkish remarks from Fed Chair Jerome... 
Via Benzinga
Topics Economy
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today